apsgb.org Report : Visit Site

Technical data of the apsgb.org

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host apsgb.org. Currently, hosted in United Kingdom and its service provider is IAAS VLAN .

the related websites

apsgb.co.uk imperial.ac.uk jpag.org port.ac.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

the academy of pharmaceutical sciences 'promoting the pharmaceutical sciences' member login join aps home my account about us events focus groups the board awards sponsorship resources useful links pfizer, lilly?s osteoarthritis pain drug meets co-primary endpoints in phase 3 study..... takeda, ovid plan to launch three trials of anti-epileptic drug tak-935/ov935..... fda accepts immunomedics? bla and grants priority review for sacituzumab govitecan to treat metastatic triple-negative breast cancer..... roche?s baloxavir marboxil succeeds in phase iii flu study..... evoke group?s expansion drive continues with west coast agency buy..... eisai obesity drug belviq may have an edge with new heart-safety data?but to what end?..... under scrutiny for cohen deal, novartis calls off further price hikes in 2018..... roche's tecentriq extends its hot streak with liver cancer combo breakthrough..... fda nails baxter with warning letter for plant picked up in claris buyout..... roche?s baloxavir marboxil reduces flu symptoms in phase iii capstone-2 study..... clinigen acquires global rights to proleukin outside us..... eureka therapeutics announces boehringer ingelheim is exercising option to license novel tcrm) antibodies..... indivior wins us court order blocking dr. reddy's sale of generic opioid treatment..... moderna opens $110m manufacturing site for its mrna program..... johnson & johnson softens fda's invokana blow with positive kidney results..... winning trump?s praise was easy for pfizer. wall street and the hill? not so much..... johnson & johnson predicts 4% to 6% net price decline in pharma this year, with remicade down by double digits in q2..... vertex says it's glad england made another offer for cf drugs, but it'll have to do better..... indivior wins us court order blocking dr. reddy's sale of generic opioid treatment..... pfizer begins pivotal phase 3 program for investigational hemophilia b gene therapy..... ironwood pharmaceuticals starts phase iiib study of linaclotide in adult patients with ibs-c..... ogilvy commonhealth?s north america ceo snags new chief creative officer..... pfizer halts production at india injectables plant after fda again finds issues..... fda joins eu in seeking recall of certain chinese-made valsartan products over potential cancer risk..... fda looks at incentives, manufacturing ?interventions? to solve drug shortages..... with fda nod, pfizer and astellas? xtandi gets its shot at blockbuster sales boost..... will mylan?s big copaxone price break force teva?s hand? clients are pushing already..... purdue defends against opioid lawsuits by pointing to fda regulations it helped create..... could amgen soften the neulasta biosimilar blow with an alexion buy?..... siga technologies gets fda nod for tpoxx to treat smallpox..... apotex to divest european generics business..... taiho pharmaceutical exercises option to develop ab928 in its territories..... bayer works to connect brand to products with all-american tv ad..... hemophilia, the musical: biomarin sponsors one-of-a-kind performance created by teens..... mccann health fires chief creative officer over conduct code violation..... fiercepharmaasia?biogen-eisai alzheimer?s win, otsuka deals, samsung biologics criminal probe..... high-stakes talc trial ends in whopping $4.7b verdict for johnson & johnson..... ms patent win boosts novartis? gilenya, helps celgene and maybe biogen too..... as u.s. trade war escalates, china rolls out red carpet for indian drugmakers..... adempas maker bayer connects hypertension patients with new mentoring group..... senators challenge novartis' account of cohen deal, calling it 'longer and more detailed' than disclosed..... genmab, immatics to develop next-generation bispecific cancer immunotherapies..... dermavant to buy rights to tapinarof from gsk for 250m..... genentech seeks fda approval for venclexta for aml..... samsung biologics to face criminal probe over accounting violation for biosims jv..... samsung biologics to face criminal probe over accounting fraud for biosims jv..... johnson & johnson enlists diabetes veteran merck kgaa to hawk invokana in china..... sen. wyden probes 'secret, sweetheart' deal between pfizer, trump..... can mylan dodge pfizer's remicade woes with a low-priced neulasta copy?..... otsuka pharmaceutical to buy biotechnology firm visterra for $430m..... abbvie?s blood cancer drug ibrutinib fails in phase 3 dlbcl trial..... fda grants priority review to merck?s sbla for keytruda to treat advanced hepatocellular carcinoma..... abbvie, johnson & johnson's imbruvica comes up short in non-hodgkin lymphoma trial..... lilly oncology?s strategy? listen to tough talk from patients?and save data for later..... tough time targeting women, pharma? think time-crunched and family-first: study..... pfizer?s bow to trump won?t just hit its own prices?it?ll put a chill on hikes, period..... bristol-myers squibb's opdivo-yervoy combo wins right to challenge merck's keytruda in rare cancer..... johnson & johnson, looking for its tremfya niche, starts up new trial program in crohn's..... pharmas call off price hikes after california law forces new warnings: report..... abbvie, j&j;'s imbruvica comes up short in non-hodgkin lymphoma trial..... biocryst terminates merger deal with idera pharmaceuticals..... celgene?s anti-pd-l1 immunotherapy plus abraxane improves pfs in breast cancer study..... us ftc approves takeda?s $62bn acquisition of shire..... biontech, genevant to co-develop mrna drugs for rare diseases..... rss newsfeed.... welcome to the academy of pharmaceutical sciences the academy of pharmaceutical sciences (aps) is the uk-based professional membership body for pharmaceutical scientists. we represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the pharmaceutical science sector. latest news call for nominations for the eminent fellowship and fellowship of the academy of pharmaceutical sciences (aps) the aps is proud to announce a call for this years nominations for two awards, the eminent fellowship (nominated by an aps member) fellowship of the academy (self-nominated by an aps member) these awards recognise and reward science from all sectors where pharmaceutical scientists work. the eminent fellowship will be presented at a social networking event held on thursday 6th september followed by this years premier uk pharmaceutical sciences conference, aps@fip conference in 2018 which will take place in glasgow on the 7th september 2018. for more information, click here professional recognition for pharmaceutical science degrees the academy of pharmaceutical sciences (aps) is delighted to announce that the pharmaceutical science course at the university of greenwich has become the first aps accredited course having successfully completed the accreditation process set up by the academy towards the end of 2017. this is the first time that a pharmaceutical science course has been accredited in the united kingdom and it is also, we believe, a world first. achieving accreditation gives assurance to students and employers that the course meets the high standards required by the academy and that these standards will be maintained throughout the 5-year period of accreditation. aps believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. the discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the uk. the academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients. aps events overview the aps has developed an exciting and informative programme for our events in 2018. dont forget to make a note of aps@fip, linking with the 78th fip world

URL analysis for apsgb.org

http://www.apsgb.co.uk/Default.asp/situations_vacant/advertise.asp
https://www.apsgb.co.uk/events/20180718/default.asp
http://www.apsgb.co.uk/resources/default.asp
http://www.apsgb.co.uk/awards/nominations.asp
https://www.apsgb.co.uk/events/20180907/default.asp
http://www.apsgb.co.uk/events/default.asp
http://www.apsgb.co.uk/Default.asp/join_us/default.asp
https://www.apsgb.co.uk/my_account/default.asp
http://www.apsgb.co.uk/usefullinks/default.asp
http://www.apsgb.co.uk/Default.asp/situations_vacant/default.asp
http://www.apsgb.co.uk/Default.asp/privacypolicy
http://www.apsgb.co.uk/focus_groups/default.asp
pfizer.co.uk
astrazeneca.co.uk
mylan.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

WHOIS LIMIT EXCEEDED - SEE WWW.PIR.ORG/WHOIS FOR DETAILS

  REFERRER http://www.pir.org/

  REGISTRAR Public Interest Registry

SERVERS

  SERVER org.whois-servers.net

  ARGS apsgb.org

  PORT 43

  TYPE domain

  REGISTERED unknown

DOMAIN

  NAME apsgb.org

NSERVER

  DNS2.4THENET.COM 173.192.101.194

  DNS7.4THENET.COM 119.81.97.170

  DNS3.4THENET.COM 193.33.179.204

  DNS5.4THENET.COM 81.95.158.50

  DNS4.4THENET.COM 52.64.171.200

  DNS1.4THENET.COM 23.236.59.22

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .